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Abstract
Introduction: Estrogen is involved in several physiological and pathological processes through estrogen receptor
(ER)-mediated transcriptional gene regulation. miRNAs (miRs), which are noncoding RNA genes, may respond to
estrogen and serve as posttranscriptional regulators in tumorigenic progression, especially in breast cancer;
however, only limited information about this possibility is available. In the present study, we identified the
estrogen-regulated miR-34b and investigated its functional role in breast cancer progression.
Methods: Estrogen-regulated miRNAs were identified by using a TaqMan low density array. Our in vivo Tet-On
system orthotopic model revealed the tumor-suppressive ability of miR-34b. Luciferase reporter assays and
chromatin immunoprecipitation assay demonstrated miR-34b were regulated by p53-ER interaction.
Results: In this study, we identified one such estrogen downregulated miRNA, miR-34b, as an oncosuppressor that
targets cyclin D1 and Jagged-1 (JAG1) in an ER+/wild-type p53 breast cancer cell line (MCF-7), as well as in ovarian
and endometrial cells, but not in ER-negative or mutant p53 breast cancer cell lines (T47D, MBA-MB-361 and MDA-
MB-435). There is a negative association between ERa and miR-34b expression levels in ER+ breast cancer patients.
Tet-On induction of miR-34b can cause inhibition of tumor growth and cell proliferation. Also, the overexpression
of miR-34b inhibited ER+ breast tumor growth in an orthotopic mammary fat pad xenograft mouse model. Further
validation indicated that estrogen’s inhibition of miR-34b expression was mediated by interactions between ERa
and p53, not by DNA methylation regulation. The xenoestrogens diethylstilbestrol and zeranol also showed similar
estrogenic effects by inhibiting miR-34b expression and by restoring the protein levels of the miR-34b targets
cyclin D1 and JAG1 in MCF-7 cells.
Conclusions: These findings reveal that miR-34b is an oncosuppressor miRNA requiring both ER+ and wild-type
p53 phenotypes in breast cancer cells. These results improve our ability to develop new therapeutic strategies to
target the complex estrogenic pathway in human breast cancer progression through miRNA regulation.
Introduction
Breast cancer is the most frequently occurring cancer in
women [1], and the majority of the cases (about 70%)
are estrogen receptor (ER)-positive (ER+) [2-4]. Acti-
vated, functional ER can stimulate tumor growth and
cell proliferation; therefore, it has been postulated that
in most ER+ breast tumors, ER is the driving force
underlying tumorigenesis, rendering it a principal target
for treatment [5,6]. The agents that antagonize estro-
genic action (for example, tamoxifen (TAM) and other
selective estrogen receptor modulators (SERMs)) are
used clinically to treat ER+ breast cancer patients. How-
ever, for some ER+ patients, these drugs are not effec-
tive for long-term use, and, in addition, many are not
responsive to hormone therapy at all [7]. Therefore, the
challenge is to further clarify the ER signaling pathway
to identify other therapeutic targets and to develop new
predictive biomarkers for better treatments.
ER signaling is complicated. ER is known to associate
with numerous cofactors that act at multiple levels,
including transcription, translation and even posttransla-
tion. The classical estrogen pathway is the direct binding
of estrogen-responsive elements by ligand-activated ER
to regulate gene expression. Estrogen may also act as a
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oncogenes in breast cancer in the nonclassical pathway
[8-10]. Furthermore, estrogen can stimulate rapid, extra-
nuclear (nongenomic) signaling events, such as the acti-
vation of the Src/Ras/Erk signaling pathway. Although
the mechanisms of estrogen signaling in breast cancer
have been extensively studied, there are still elusive
interactions to be elucidated.
miRNAs (miRs) are an evolutionarily conserved class
of small, noncoding RNAs of approximately 22 nucleo-
tides that decrease gene expression posttranscriptionally
by complementary binding to the mRNA 3’UTR in a
sequence-specific manner, resulting in cleavage or trans-
lational repression of the target mRNA [11]. Many miR-
NAs have been correlated with various kinds of cancers
and function as oncogenes or tumor suppressor genes
[12]. Recently, the miRNA expression profile for breast
cancer has been reported in a study in which compari-
sons between normal and tumorous breast tissues
revealed that miR-10b, miR-125b and miR-145 were
downregulated and that miR-21 and miR-155 were
upregulated [13]. Furthermore, studies comparing
miRNA profiles in breast cancer with different ER/pro-
gesterone (PR)/HER2 levels showed that specific miRNA
expression levels could be correlated to different ER/PR
status (miR-142-5p, miR-200a, miR-205 and miR-25)
and HER2 status (let-7f, let-7g, miR-107, miR-10b, miR-
126, miR-154 and miR-195) [14]. These studies suggest
that miRNAs could play pivotal roles in the pathological
and molecular functions in the tumorigenesis of breast
cancer. Hormone-regulated miRNAs might be potential
therapeutic targets or might serve as prognostic markers
for hormone-dependent tumors. However, few studied
have focused on hormone regulation of miRNAs in
breast cancer.
To identify estrogen-regulated miRNAs in breast can-
cer, we examined the miRNA profile of the ER+ breast
cancer cell line MCF-7 with and without estrogen treat-
ment using a real-time, quantitative PCR (qPCR)-based
TaqMan low density array (TLDA; Applied Biosystems,
Foster City, CA, USA). One of the estrogen-regulated
miRNAs, miR-34b, has been identified and has been
functionally validated as a tumor suppressor miRNA
downregulated by estrogen. We demonstrate herein that
estrogen regulates the promoter activity of miR-34b
gene through the interaction between ER and p53. Pre-
vious studies showed that miR-34b has important func-
tions in cell proliferation and apoptosis and also serves
as a direct transcriptional target of p53 [15-17]. Herein,
on the basis of clinical and in vivo animal models, we
show that miR-34b may play a role in controlling the
growth of ER+ breast cancer. The evidence we present
suggests that miR-34b is a crucial factor in ER+ breast
cancer tumorigenesis and may serve as a target for
miRNA-based breast cancer therapy or as a miRNA-
based prognostic marker, and we provide new insights
into breast cancer treatments.
Materials and methods
Patient tissue specimens
Specimens from 47 breast cancer patients were used for
miRNA analysis. The study was approved by the Institu-
tional Review Board of the National Taiwan University
Hospital, Taipei, Taiwan. Written informed consent was
obtained from all patients. Frozen sections of breast
cancer tissue were obtained when patients underwent
surgical resection of breastt u m o r sa tt h eN a t i o n a lT a i -
wan University Hospital between December 2003 and
December 2006. The 47 clinical samples were grouped
according to pathological classification, which included
the ER, PR and HER2 status. Of these specimens, 26
samples were ER+ and 21 samples were ER-negative
(ER-). The clinical characteristics of the breast cancer
patients are listed in Table 1. None of these patients
had received adjuvant chemotherapy.
Cells and treatments
MCF-7 cells were purchased from America Type Cul-
ture Collection (ATCC; Manassas, VA, USA). The cells
were maintained in 10% fetal bovine serum (FBS) as
prescribed. MDA-MB-361, MDA-MB-435, T47D and
OVCAR4 cells were purchased from among the NCI-60
cell lines (Developmental Therapeutics Program,
National Cancer Institute, Frederick, MD, USA) and cul-
tured in RPMI 1640 with 10% FBS as prescribed. 293T
cells were purchased from ATCC and maintained in
10% FBS as prescribed. The ligands 17b-estradiol (E2),
4-hydroxytamoxifen (4-OHT), diethylstilbestrol (DES)
and zeranol (ZEA) were purchased from Sigma-Aldrich
(St Louis, MO, USA). Before MCF-7 cells were treated
with ligands, the medium was replaced with phenol red
free a-MEM (Life Technologies, Rockville, MD, USA)
containing 10% dextran charcoal-stripped FBS (Thermo
Table 1 Clinical characteristics of breast cancer patients
Patient demographics ER+ ER- P-
value
Patients, n (%) 26 (55.32%) 21 (44.68%)
Mean age ± SD (years) 53.44 ± 13.79 54.95 ± 10.13 0.68
a
Tumor stage, n (%)
Stage I 11 (42.31%) 8 (38.10%) 0.7699
b
Stages II and III 15 (57.69%) 13 (61.90%)
Tumor type, n (%)
HER2+ 15 (57.69%) 12 (57.14%) 0.9698
b
HER2- 11 (42.31%) 9 (42.86%)
5-year disease-free survival, n
(%)
16 (61.54%) 13 (61.90%) 0.9795
b
ER = estrogen receptor.
at-test;
bc
2 test.
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Page 2 of 16Fisher Scientific Inc, Waltham, MA, USA) for 3 days.
Cells were treated with 10 nM E2, 100 nM 4-OHT, 10
nM DES or 10 nM ZEA for 24 hours prior to analyses.
Proliferation assay
A 3-(4,5-dimethylthiozol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) (Sigma-Aldrich) assay was performed to
determine cell proliferation. Briefly, MCF-7 cells were
plated in 96-well plates at a density of 5 × 10
3/well.
After 24-hour incubation, cells were serum-starved over-
night. The cells were then treated with different concen-
trations of estrogen for indicated times, then culture
medium containing 0.5 mg/ml MTT solution was added
to each well. After 1.5-hour incubation, the medium was
removed and dimethyl sulfoxide was added to the wells.
The color intensity of solubilized formazan was mea-
sured at 570 nm with an ELISA plate reader (VICTOR
X3 Multilabel Plate Reader; PerkinElmer, Waltham, MA,
USA).
Anchorage-dependent colony formation assay
Six-well plates were used for seeding 100 cells in a-
MEM supplemented with 10% FCS. E2 and 4-OHT
were added to the plate at different concentrations every
2 days. Plates were incubated in a 37°C incubator for 2
weeks. The number of colonies was counted after they
were stained with 0.05% crystal violet (Sigma-Aldrich)
for 1 hour and washed extensively with PBS.
TaqMan Low Density Array
The human miRNA TLDA contains eight sample-load-
ing lines, each of which is connected by a microchan-
nel to 48 miniature reaction chambers for a total of
384 wells per card. It contains 365 different human
miRNA assays plus two carefully selected small nucleo-
l a rR N A s( s n R N A s )t h a tf u n c t i o na se n d o g e n o u sc o n -
trols for data normalization. The human miRNA
TLDA was used in conjunction with Multiplex reverse
transcriptase (RT; Applied Biosystems) consisting of
eight predefined RT primer pools containing up to 48
RT primers each. All 365 miRNA targets were reverse-
transcribed in eight separate RT reactions, and each
RT reaction was pipetted into one of the eight filling
ports on the TaqMan array. To perform PCRs, we
used a 7900HT Fast Real-Time PCR System (Applied
Biosystems), and SDS version 2.3 software (Applied
Biosystems) was used for comparative differential
expression (ΔCt) analysis.
Quantitative real-time PCR analysis of miRNA expression
Total RNAs were extracted from cells using TRIzol
reagent (Invitrogen/Life Technologies, Carlsbad, CA,
USA). miRNAs were quantified using TaqMan miRNA
assays (Applied Biosystems). U6B was used for
normalization of miRNA expression. The PCR was run
in a 7900HT Fast Real-Time PCR System, and SDS ver-
sion 2.3 software (Applied Biosystems) was used for
comparative ΔCt analysis. Experiments were performed
three times in triplicate.
Western blot analysis
MCF-7 cells were treated with the chemicals described
above. Cells were washed twice with ice-cold PBS and
collected for protein extraction. Protein was extracted
by using mammalian protein extraction reagent (Pierce
Biotechnology, Inc, Rockford, IL, USA) containing pro-
tease inhibitors (Sigma-Aldrich). SDS-PAGE with 10%
resolving gel was used to separate proteins (25 mg/lane).
Mouse anti-cyclin D1 mAb (Merck KGaA, Darmstadt,
Germany), mouse anti-Jagged-1 (anti-JAG1) mAb (Santa
Cruz Biotechnology, Santa Cruz, CA, USA) and mouse
anti-b-actin mAb (Santa Cruz Biotechnology) were all
used according to the manufacturer’s instructions.
Bound antibodies were detected using an enhanced che-
miluminescence system (Santa Cruz Biotechnology).
Chemiluminescent signals were captured using the Fuji-
film LAS-3000 system (Fujifilm, Tokyo, Japan). All
experiments were performed at least three times in
triplicate.
Vectors and constructs
We used the pSilencer 4.1-CMV puro vector (Applied
Biosystems), the pTRE-Tight vector (631059; Clontech
Laboratories, Inc, Mountain View, CA, USA) and the
Tet-On vector (Clontech Laboratories, Inc) in the plas-
mid constructs. A precursor form of miR-34b was
inserted into the pSilencer 4.1-CMV puro vector, then
subcloned into the pTRE-Tight vector for overexpres-
sion. Primer sequences are shown in Additional file 1,
Supplementary Table 1.
Stable clone and precursor miRNA transfection
MCF-7 cells were plated in six-well plates at a density of
5×1 0
5 cells per well in Opti-MEM Reduced Serum
Medium (Life Technologies) supplemented with 10%
FBS. Lipofectamine 2000 transfection reagent (Invitro-
gen/Life Technologies) and pTRE-miR-34b and Tet-On
plasmids were mixed according to the manufacturer’s
instructions and added to the cells. After 6 hours of
incubation, the medium was changed with fresh a-
MEM plus 10% FBS. After cotransfection of the two
plasmids, stable clones were selected by addition of neo-
mycin (1 mg/μl ) .P r e c u r s o rm i R N A s ,a n t a g o m i r sa n d
negative controls (mock transfection) were obtained
from Applied Biosystems. For precursor miRNA, cells
were transfected with Lipofectamine LTX (Invitrogen/
Life Technologies) with 6 nM precursor miRNA and
harvested 48 or 72 hours later.
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Genomic DNA was extracted from MCF-7 cells using
the QIAamp DNA Mini Kit (QIAGEN, Valencia, CA,
USA). Genomic DNA (2 μg) was modified by sodium
bisulfite using the EZ DNA Methylation Kit (Zymed
Research Corp, Irvine, CA, USA). Methylation-specific
PCR (MSP) and bisulfite-sequencing PCR (BSP) analysis
were then performed as described previously [18]. Pri-
mers for MSP and BSP were designed by using the
MethPrimer software program [19]. Primer sequences
are shown in Additional file 1, Supplementary Table 1.
Promoter reporter assay
Upstream regions of miR-34b/c were amplified by PCR
and then cloned into the pGEM-T Easy Vector System
(Promega, Madison, WI, USA). Each PCR primer carried
a5 ’ overhang that contained a HindIII recognition site.
After verification of the sequences, miR-34b/c fragments
were excised using HindIII and ligated into a pGL3-
Basic vector (Promega). In addition, oligonucleotide
fragments corresponding to p53-responsive elements
were synthesized and inserted upstream of the miR-34b/
c promoter in the pGL3-Basic vector. Cells (5 × 10
4 per
well in 24-well plates) were transfected with 100 ng of
one of the reporter plasmids using Lipofectamine 2000
reagent (Invitrogen/Life Technologies). For cotransfec-
tion of reporter genes with ER expression plasmid, equal
numbers of cells were cotransfected with 100 ng of one
of the reporter plasmids, 100 ng of pcDNA 3.1-ER (Invi-
trogen/Life Technologies) or an empty vector. The
pGL3-Basic vector without an insert served as the nega-
tive control. Luciferase activity was measured 48 hours
after transfection using a Dual-Luciferase Reporter
Assay System (Promega). Primer sequences are shown
in Additional file 1, Supplementary Table 1.
Luciferase reporter assay
The 3’UTRs of human JAG1 and cyclin D1 were ampli-
fied from human genomic DNA and cloned into a
pMIR-REPORT miRNA Expression Reporter Vector
System (Ambion/Life Technologies) by directional clon-
ing. The resultant plasmid was designated Luc-JAG1-
3’UTR-WT and Luc-CyclinD1-3’UTR-WT. To generate
the Luc-JAG1-3’UTR-Mut and Luc-CyclinD1-3’UTR-
Mut construct, seed regions were mutated by removing
complementary nucleotides of miR-34b. 293T cells (3 ×
10
5 per well) were cotransfected with a 0.5-μg firefly
luciferase reporter vector and a 0.05-μg control vector
containing Renilla luciferase, pRL-SV40 (Promega),
using Lipofectamine 2000 reagent (Invitrogen/Life Tech-
nologies) in six-well Costar plates (Corning Life
S c i e n c e s ,L o w e l l ,M A ,U S A ) .F o re a c hw e l l ,2 0 0p M
miR-34b precursor molecule (Ambion/Life Technolo-
gies) or a negative control (mock) precursor miRNA
(Ambion/Life Technologies) was cotransfected with the
reporter constructs. Luciferase assays were performed 24
hours after transfection (Dual-Luciferase Reporter Assay
System; Promega). Firefly luciferase activity was normal-
ized to Renilla luciferase activity.
Chromatin immunoprecipitation assay
The chromatin immunoprecipitation (ChIP) assays were
carried out as described previously [20]. Chromatin was
immunoprecipitated for 16 hours at 4°C using 10 μl each
of anti-RNA polymerase II, clone CTD4H8 (Millipore,
Billerica, MA, USA), normal mouse immunoglobulin G
(IgG; Millipore) and anti-ERa,c l o n eH C - 2 0( S a n t aC r u z
Biotechnology). In addition, 1/100 of the solution collected
before adding the antibody was used as an internal control
for the amount of input DNA. PCR was carried out in a
20-μl volume containing 1/100 of the immunoprecipitated
DNA, blend Taq polymerase and 5 μM of each primer.
The PCR protocol entailed initial denaturation for 3 min-
utes at 94°C and 33 cycles of 20 seconds at 94°C, 30 sec-
onds at 59°C and 30 seconds at 72°C, followed by a final
extension at 72°C for 2 minutes. Primer sequences are
shown in Additional file 1, Supplementary Table 1.
Orthotopic mammary fat pad xenograft mouse model
This study was approved by the Institutional Review Board
and the Animal Care and Use Committee at National Tai-
wan University. The survival rate of transfected MCF-7
cells was determined by counting cell numbers using try-
pan blue. Transfected MCF-7 cells (1 × 10
6 live cells in
100 μlH a n k ’s balanced salt solution) were injected into
the mammary fat pads of 5-week-old NOD SCID mice
(supplied by the animal center at the College of Medicine,
National Taiwan University). To determine whether miR-
34b could reduce orthotopic tumor growth, the mice were
randomized into two groups (n = 10 for each group): (1)
miR-34b Tet-On overexpression stable clone without dox-
ycycline (Sigma-Aldrich) or (2) miR-34b Tet-On overex-
pression clone with doxycycline. Mice were injected with
doxycycline (2 mg/ml) in water [21,22] after tumor size
reached 5 mm
3. Tumor sizes were monitored every 7 days
by using electronic vernier calipers, and the tumor volume
(V) was calculated by using the formula V =0 . 4×ab
2,
where a and b are the longest and shortest diameters of
each tumor, respectively.
Immunohistochemistry
We performed immunohistochemistry by using 5-μm
formalin-fixed, paraffin-embedded tissue sections, pla-
cing them on silane-coated slides and baking them at
70°C overnight. Afterward the slides were deparaffinized,
hydrated, placed in 10 mM citrate buffer (pH 6) and
microwaved for a total of 20 minutes for antigen retrie-
val. After cooling, the slides were treated with 3% H2O2
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Triton X-100) for 1 hour and anti-cyclin D1, clone H-
295 (Santa Cruz Biotechnology) rabbit pAb was used.
Rabbit IgG (Millipore) was used as a negative control.
We used the VECTASTAIN Elite ABC Kit (Vector
Laboratories, Burlingame, CA, USA) for detection.
Chromagen diaminobenzidine (Vector Laboratories) was
used, and sections were counterstained with H & E.
Statistical analysis
All experiments were performed in triplicate and analyzed
for significant differences by analysis of variance using
Microsoft Excel software (Microsoft Corp, Redmond, WA,
USA). P < 0.05 was considered statistically significant.
Where appropriate, the data are presented as means ± SD.
Results
Estrogen-regulated miRNA profile in ER+ breast cancer
cells
To investigate whether estrogen regulates miRNA
expression, the ER+ human breast cancer cell line MCF-
7 was treated with 10 nM E2 for 24 hours, and changes
in the miRNA expression profile were analyzed by per-
forming qPCR-based TLDA miRNA assays. Table 2 lists
t h e2 6m i R N A st h a tw e r es i g n i f i c a n t l yd o w n r e g u l a t e d
and the 28 miRNAs that were significantly upregulated
(greater than fivefold changes) by E2 treatment of MCF-
7 cells. Among these estrogen-regulated miRNAs, miR-
34b has been shown to regulate tumor progression in a
variety of cancers [15-17,23-25]. Because E2 markedly
decreased miR-34b expression levels (72-fold), miR-34b
was chosen for further study.
Negative correlation of miR-34b expression level and ER
status in ER+ human breast cancers
We next examined the expression levels of miR-34b in
47 human breast cancer patients (Table 2). We found
that the ER+ tissues had lower miR-34b expression
levels compared to ER- tissues (ER+: n =2 6v sE R - :n =
21; P <0 . 0 5 )( F i g u r e1 A ) .M o r e o v e r ,t h ec o r r e l a t i o n
between miR-34b and ER expression levels were inver-
sely correlated (Pearson coefficient = -0.4185, P =
Table 2 Estrogen-regulated miRNA profiles of ER+ breast cancer cell line MCF-7 using TaqMan Low-Density Array
Downregulated miRNAs Upregulated miRNAs
miRNAs Fold change P-value miRNAs Fold change P-value
miR-509 -119.389 <0.001 miR-189 5.024565 0.002
miR-376a -102.459 <0.001 miR-326 5.52856 <0.001
miR-629 -91.9202 <0.001 miR-520c 5.619023 <0.001
miR-34b -71.9166 <0.001 miR-520b 5.787208 <0.001
miR-519d -63.3272 <0.001 miR-329 6.293726 <0.001
miR-33 -41.4439 <0.001 miR-17-3p 7.373741 <0.001
miR-515-5p -40.7382 <0.001 miR-369-3p 8.591994 <0.001
miR-624 -38.3289 <0.001 miR-519c 8.613923 <0.001
miR-34c -37.07 <0.001 miR-524 11.21323 <0.001
miR-551b -33.1565 <0.001 miR-576 13.31873 <0.001
miR-564 -27.6564 <0.001 miR-653 13.9337 <0.001
miR-449 -25.5663 <0.001 miR-383 15.40733 0.004
miR-10b -22.5561 <0.001 miR-627 15.45773 <0.001
miR-518e -22.0561 <0.001 miR-105 16.18497 0.001
miR-139 -21.8713 <0.001 miR-616 20.96113 0.032
miR-520h -18.821 <0.001 miR-422b 24.21192 0.018
miR-453 -17.2921 <0.001 miR-452 28.38138 <0.001
miR-526b -10.5159 0.014 miR-380-5p 33.71417 0.007
miR-371 -9.59159 <0.001 miR-548b 42.83806 <0.001
miR-656 -8.11175 0.001 miR-521 44.27376 0.005
miR-124a -6.73618 <0.001 miR-579 45.54916 <0.001
miR-518f -5.80659 0.002 miR-142-5p 51.74748 <0.001
miR-135a -5.40944 <0.001 miR-519e 53.65128 <0.001
miR-485-5p -5.01188 0.003 miR-185 55.94657 <0.001
miR-493 92.40058 <0.001
miR-515-3p 97.85771 <0.001
ER = estrogen receptor. The expression profiles of miRNAs which have at least fivefold changes in expression. We used U6B expression as the internal control to
normalize expression levels between the two groups. Experiments were repeated in triplicates. Relative expression = 2^
-(with 10 nM estradiol/without estradiol).
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Page 5 of 16Figure 1 Negative correlation of miRNA (miR)-34b expression level and estrogen receptor (ER) status in ER+ human breast cancers. (A)
miR-34b expression in human breast cancer tissue. miR-34b expression levels were analyzed by quantitative PCR (qPCR) (ER+, n = 26; ER-, n =
21). The results are normalized to internal U6 snRNA expression. (B) Correlation analysis of ERa and miR-34b in ER+ human breast cancer tissues.
P = 0.019. (C) Correlation analysis of ERa and miR-34b in ER- human breast cancer tissues. P = 0.968. For both parts (B) and (C),E R a mRNA
expression levels were analyzed performing SYBR Green qPCR for each tissue sample. Data represent means ± SD of triplicate experiments (*P <
0.05). The results are normalized to internal TaqMan Low-Density Array expression.
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relation of miR-34b and ER showed no significance for
ER- patients (Pearson coefficient = 0.009, P = 0.9679)
(Figure 1C). These data suggest that miR-34b expression
is closely linked to ERa expression levels in ER+ human
breast tumors involved in the complexity of in vivo
systems.
Estradiol increased anchorage-dependent colony
formation and repressed miR-34b expression in MCF-7
cells
To verify that miR-34b expression is linked to tumor
growth, MCF-7 cells were treated with different concen-
trations of E2 (0.1, 1.0, 10 and 100 nM), and cell prolif-
eration rates were determined. E2 increased anchorage-
dependent growth in a concentration-dependent manner
( F i g u r e2 A ) ,b u tt h ee x p r e s s i o nl e v e l so fm i R - 3 4 b
decreased concentration-dependently. E2 (10 nM) treat-
ment reduced miR-34b expression by 88% in MCF-7
cells (Figure 2B). The inhibitory effect of estrogen on
miR-34b expression was apparent within 2 hours and
was sustained for at least 24 hours in MCF-7 cells (Fig-
ure 2B). Transfection of precursor miR-34b or antago-
mir-34b also showed significant decreases or increases
in cell proliferation (Figure 3A). These data suggest that
miR-34b may serve as a tumor suppressor that regulates
tumor progression, as has been reported in a variety of
cancers [15-17,23-25].
miR-34b suppressed cell proliferation by direct regulation
of Jagged-1 and cyclin D1
Previous studies have shown that high expression of
cyclin D1 and Jagged-1 correlate with poor prognosis in
breast cancer [26-28]. According to miRNA target gene
prediction software, including PicTar, miRanda and
miRNAMap, miR-34 could target key regulators of cell
proliferation, including cyclin D1 and JAG1 (Figure 3B).
To investigate the possible link between miR-34b and
Figure 2 Estradiol (E2) increased anchorage-dependent colony formation and repressed miRNA (miR)-34b expression. (A) Anchorage-
dependent colony formation assay results. MCF-7 cells were seeded into six-well plates and treated with different concentrations of E2 (0 to 10
nM) for 14 days. Colonies were fixed and stained with crystal violet dye. Representative results are shown in the upper panel. The number of
colonies are shown in the bottom panel (n = 3). (B) miR-34b expression of MCF-7 cells treated with E2 (10 nM) for different time periods (n =3 )
or with different concentrations of E2 for 24 hours (n = 3). The results were normalized to internal U6 snRNA expression. (C) Western blots of
cyclin D1 in MCF-7 cells treated with E2 (10 nM) for different time periods (n = 3) or with different concentrations of E2 for 24 hours (n = 3). b-
actin was probed as an internal control. The results are expressed as means ± SD. *P < 0.05. (D) Stable clones of pTRE-miR-34b/Tet-On were
induced by doxycycline (DOX) (2 μM) for 48 hours, and miR-34b expression was analyzed by performing quantitative PCR. (E) Cell viability of
pTRE-miR-34b/Tet-On in the presence or absence of DOX (2 μg/ml) was detected by using 3-(4,5-dimethylthiozol-2-yl)-2,5-diphenyltetrazolium
bromide (n = 3). (F) Western blot showing cyclin D1 after miR-34b induction. b-actin was probed as an internal control.
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sion levels of cyclin D1 and JAG1 were examined. As
shown in Figure 2C, both cyclin D1 and JAG1 were
upregulated by treatment with E2 in a concentration-
and time-dependent manner. Moreover, overexpression
of precursor miR-34b leads to downregulation of JAG1
and cyclin D1 (Figure 3C).
To further confirm the interaction between miR-34b
and its putative target genes, we cloned the JAG1 and
cyclin D1 3’UTR sequence and inserted it downstream
of the firefly luciferase coding region of the pMIR-
REPORT vector (Figures 3D and 3E). Mutants with the
putative binding sites were prepared as described above
(see Materials and methods). Our results show that the
luciferase activity of the wild-type JAG1 and cyclin D1
3’UTR construct was significantly inhibited after the
introduction of miR-34b into 293T cells, but not by the
negative control. Mutations of the 3’UTR-binding sites
completely abolished the ability of miR-34b to regulate
luciferase expression (Figures 3D and 3E). These results
demonstrate that JAG1 and cyclin D1 are potential tar-
gets of miR-34b. Furthermore, these data suggest that
miR-34b may suppress tumor growth through the sup-
pression of cyclin D1 and JAG1 expression.
miR-34b inhibited tumor growth in mouse mammary fat
pads xenografted with MCF-7 pTRE-miR-34b/Tet-On
stable clones
Since we observed that miR-34b was downregulated in
ER+ breast cancer cells (MCF-7 cells), we speculated
Figure 3 miRNA (miR)-34b suppressed cell proliferation by directly regulating JAG1 and cyclin D1. (A) Cell viability after transfection of
negative control (Mock) (200 pM), precursor miR-34b (200 pM) or antagomir-34b (200 pM) was detected by using 3-(4,5-dimethylthiozol-2-yl)-2,5-
diphenyltetrazolium bromide (n = 3). (B) Predicted binding structures of miR-34b with targets JAG1 and cyclin D1. RNAhybrid software was used
for nucleotide-binding sequence prediction. (C) Western blots showing JAG1 and cyclin D1 after 24-hour treatment with precursor miR-34b or
(200 pM) in MCF-7 cells. b-actin was probed as internal control. The numbers under the blots represent the semiquantitative values of the
Western blot analysis. (D) and (E) Top: Diagrams depicting the pMIR-REPORT vector luciferase reporter constructs containing a cytomegalovirus
(CMV) promoter (PCMV), which was used to verify the putative miR-34b binding sites. Bottom bar graphs: 293T cells were cotransfected with
negative control (Mock) (200 pM) or miR-34b (200 pM), Luc-JAG1-3’UTR (0.5 μg) or Luc-CyclinD1-3’UTR (0.5 μg), along with a pRL-SV40 reporter
plasmid (0.05 μg). After 24 hours, luciferase activity was measured. Values are presented as relative luciferase activity after normalization to Renilla
luciferase activity. Data are expressed as means ± SD of results derived from triplicate experiments. *P < 0.05.
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Page 8 of 16that overexpression of miR-34b might inhibit cell prolif-
eration. To test this hypothesis, we established a miR-
34b Tet-On overexpression system. In this system, miR-
34b is conditionally turned on by doxycycline treatment
(Figure 2D). Addition of doxycycline significantly
decreased cell proliferation (Figure 2E) and cyclin D1
expression (Figure 2F) in MCF-7/miR-34b Tet-On stable
clones. Doxycycline did not exert significant effects on
cell growth and cyclin D expression in parental and
mock transfection of MCF-7 cells (Additional file 2, Fig-
u r eS 1 ) .T ot e s tw h e t h e rm i R - 3 4 bs u p p r e s s e st u m o r
growth in vivo,1×1 0
6 MCF-7/miR-34b Tet-On stable
clones were injected into the mammary fat pads of
f e m a l eN O DS C I Dm i c e .T u m o r size increased signifi-
cantly with time. Doxycycline was applied to induce
miR-34b expression after tumor size reached 5 mm
3.
Seven days after induction, the induced miR-34b group
showed significant reduction in tumor size compared to
the control group (P < 0.05) (Figure 4A). After 28 days,
the mice were killed and the tumor volumes were com-
pared. As shown in Figure 4B, the tumor volumes in the
induced miR-34b group were significantly lower than in
the control group (P < 0.01). H & E staining of the fat
pads confirmed that miR-34b induction led to a
decrease in tumor size (Figure 4C). The miR-34b
expression level in Tet-On group was increased 2.76-
fold compared to the noninduced miR-34b group (Fig-
ure 4D). In agreement with these findings, the expres-
sion levels of cyclin D1 were significantly reduced in the
doxycycline induced group as shown by immunohisto-
chemical staining (Figure 4E).
p53-dependent regulation of miR-34b expression by
estradiol
To investigate how E2 regulates miR-34b, we screened
the miR-34b promoter for the presence of ER-responsive
elements. However, we could not find any possible bind-
ing sites of ER in the miR-34b promoter. This result
showed that E2 regulation of miR-34b does not occur
through classical ER signaling. Recent studies showed
that p53 could bind to miR-34b/c and regulate its
expression [16]. Furthermore, the interaction between
p53 and ER at the promoter site plays a pivotal role in
the regulation of miR-34b expression [29-31].
We first demonstrated that miR-34b promoter activity
was significantly inhibited by 10 nM E2 treatment of
293T cells cotransfected with ER (Figure 5A). In addi-
tional experiments, we used breast cancer cell lines
bearing different p53 and ER status (MCF-7, T47D and
MDA-MB-435). Only cells expressing both wild-type
Figure 4 miRNA (miR)-34b inhibited tumor growth in mouse mammary fat pads xenografted with MCF-7 pTRE-miR-34b/Tet-On stable
clones. (A) Tumor size was calculated by using the formula V = 0.4 × ab
2, where a and b are the longest and shortest diameters of each
tumor, respectively. Relative tumor size was normalized by the tumor size measured at day 0 (n = 10). Day 7, P = 0.05; day 14, P = 0.0079; day
21, P = 0.0052; day 28, P = 0.0061. (B) Left: Photomicrographs of orthotopic tumors excised from mice. Right: Tumor volume of the orthotopic
tumor tissues from doxycycline (DOX)-treated mice (n = 10). (C) H & E-stained tumor tissue sections from each group. (D) Quantitative analysis
of miR-34b expression in orthotopic tumors (n = 10). The results are normalized to internal U6 snRNA expression and represent means ± SD. *P
< 0.05; **P < 0.01. (E) Immunohistochemical staining of proliferation marker cyclin D1 in orthotopic tumor tissues. IgG = immunoglobulin G.
Formalin-fixed, paraffin-embedded tissue sections were prepared and stained as indicated. Bar = 200 μM.
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Page 9 of 16Figure 5 p53-dependent regulation of miRNA (miR)-34b expression by 17b-estradiol (E2). (A) Reporter plasmids in which the luciferase
coding sequence that had fused to the miR-34b promoter region were transfected into 293T cells in conjunction with either pcDNA3.1 plasmid
coding with ER were cotransfected. Normalized luciferase activities are presented (n = 4). (B) miR-34b expression after E2 treatment in a subset
of breast cancer cells (MCF-7, T47D and MDA-MB-435) with different estrogen receptor (ER) and p53 status (n = 3). The results are normalized to
internal U6 snRNA expression and represent means ± SD. *P < 0.05. wt = wild type; mut = mutation. (C) Chromatin immunoprecipitation (ChIP)
assays of MCF-7 cells treated with or without 10 nM E2. The results of PCRs of the two p53-responsive elements after ChIP with ERa or p53 in
MCF-7 cells are indicated. Input = 1% of total lysate. IgG = immunoglobulin G. (D) Quantitative PCR of miR-34b expression in MCF-7 cells
following 10 nM E2 treatment (24 hours) and 2 μM 5-aza-2’-deoxycytidine (5-AZA) (72 hours) (n = 3). The results are normalized to internal U6
snRNA expression and represent means ± SD. *P < 0.05. CTRL = control. (E) Methylation-specific PCRs of miR-34b/c CpG islands in MCF-7 cells
after 10 nM E2 treatment. Bands in the ‘’M’’ lanes are PCR products obtained with methylation-specific primers. Those in the ‘’U’’ lanes are
products obtained with non-methylation-specific primers. (F) Bisulfite sequencing of miR-34b/c CpG islands in the indicated breast cancer cell
lines with the same treatments shown in part (D). Open and filled circles represent unmethylated and methylated CpG sites, respectively. Each
treatment group was assayed in seven replicate experiments.
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Page 10 of 16p53 and ERa responded to estrogen repression of miR-
34b (Figure 5B). These data suggest that both ER and
p53 activity are required for E2 to repress miR-34b. We
next examined whether both proteins bind to the two
p53 binding sites in the miR-34b promoter. ChIP assays
c o n f i r m e dt h a tb o t hp 5 3a n dE Rb i n dt ot h em i R - 3 4 b / c
promoter in the absence of E2 (Figure 5C). Binding of
p53 to the two p53RE binding sites of the miR-34b pro-
moter region were disrupted by treatment of cells with
E2 (Figure 5C). These data support the notion that E2’s
binding to ER may affect p53’s binding to miR-34b pro-
moter through p53-ER interaction.
Previously presented evidence indicated that miR-34b/
c expression may be regulated by DNA methylation
[18]. To investigate whether E2 could regulate miR-34b/
c through DNA methylation, we examined the methyla-
tion status of the miR-34b/c promoter. Treatment of
MCF-7 cells with a DNA methyltransferase inhibitor, 5-
aza-2’-deoxycytidine (5-aza-dC), increased the expres-
sion level of miR-34b (Figure 5D) and reduced the
methylation status in the CpG islands of the miR-34b
promoter region as demonstrated by MSP and BSP (Fig-
ure 5E). However, treatment of cells with E2 did not
cause significant differences in DNA methylation (Figure
5F). These data suggest that E2 did not regulate miR-
34b/c expression through DNA methylation in MCF-7
cells.
Xenoestrogens and tamoxifen regulate miR-34b
expression in breast cancer cells
Some xenoestrogens may play a causative role in breast
cancer tumorigenesis [32-35]. To investigate whether
xenoestrogen could promote cancer progression by reg-
ulating miR-34b (similarly to E2), we examined miR-34b
and its downstream target’s expression level after
xenoestrogen treatment. Our results show that the
xenoestrogens DES and ZEA downregulate miR-34b
expression in MCF-7 cells (Figure 6A). TAM, a SERM
that exhibits antiestrogenic effects in breast tissue, did
not affect miR-34b expression levels in MCF-7 cells
Figure 6 Xenoestrogen- and tamoxifen-regulated miRNA (miR)-34b expression in breast cancer cells. (A) miR-34b expression in MCF-7
cells after 24-hour treatment with estradiol, xenoestrogens or tamoxifen (n = 3). The results are normalized to internal U6 snRNA expression.
CTRL = control; E2 = 10 nM 17b-estradiol; DES = 100 nM diethylstilbestrol; ZEA = 100 nM zeranol; TAM = 100 nM tamoxifen. (B) Western blot of
cyclin D1 after 24-hour treatment with E2, xenoestrogens or TAM in MCF-7 cells. b-actin was probed as an internal control. Graphs at bottom
present the Western blot analysis quantitative data (n = 3). (C) Western blot of JAG1 in MCF-7 after 24-hour treatment with E2, xenoestrogens or
tamoxifen (n = 3). E2 = 10 nM estradiol; DES = 100 nM diethylstilbestrol; ZEA = 100 nM zeranol; TAM = 100 nM tamoxifen. b-actin was probed
as an internal control. (D) Quantitative PCR of miR-34b/c expression in MCF-7 cells following 10 nM E2, 100 nM TAM or combined treatment (n
= 3). The results were normalized to internal U6 snRNA expression. (E) Western blot showing JAG1 in MCF-7 after 24-hour treatment with E2,
tamoxifen or combined treatment (n = 3). E2 = 10 nM estradiol; TAM = 100 nM tamoxifen. b-actin was probed as an internal control. (F)
Quantitative expression of miR-34b and miR-34c after E2 treatment in MCF-7 breast cancer cells, mouse primary endometrial cells and OVCAR4
ovarian cancer cells (n = 3). The results were normalized to internal U6 snRNA expression and are expressed as means ± SD. *P < 0.05.
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Page 11 of 16(Figure 6A). In agreement with this finding, the protein
levels of cyclin D1 and JAG1 were upregulated by treat-
ment with DES and ZEA, whereas TAM had no signifi-
cant effect (Figures 6B and 6C).I m p o r t a n t l y ,c o m b i n e d
estrogen and TAM treatment reversed the effect of
estrogen on miR-34b (Figures 6D and 6E).
To investigate whether the regulation of miR-34b
expression is tissue-specific, we studied human
OVCAR4 ovarian cancer cells and primary culture of
mouse endometrial cells. Both of these cells are p53+/+
and E2-responsive. As shown in Figure 6F, E2 downre-
gulated miR-34b/c expression in both OVCAR4 and
endometrial cells. These data suggest that the E2 regula-
tion of miR-34b/c maybe a universal event and might
also contribute to the proliferation potential in these
tissues.
miR-34b/c suppresses cell growth in breast cancer cell
lines
To evaluate this possibility by using miR-34b/c as
potential therapeutic targets, we obtained four breast
cancer cell lines with different ER and p53 status and
overexpressed miR-34b/c. Among the four cell lines,
MCF-7 expresses ER+ and wild-type p53 (ER+/p53
wt),
both T47D and MDA-MB-361 are ER+ and p53-mutant
(ER+/p53
mut), and MDA-MB-435 is ER- and p53-
mutant (ER-/p53
mut) .A ss h o w ni nF i g u r e7 ,d e s p i t et h e
different status of ER and p53, all four cell lines showed
a significant decrease in growth after 48 hours with the
expression of miR-34b/c. This result demonstrates that
the induction of miR-34b/c could suppress cell growth
and that the effect was not influenced by ER or p53
status.
Discussion
Hormone-regulated miRNAs may be potential therapeu-
tic targets in hormone-dependent tumors. However, few
studies have focused on hormone-regulated miRNA
expression in breast cancer. In the present study, we
analyzed the estrogen-regulated miRNA expression pro-
file in MCF-7 breast cancer cells. We found a set of 54
miRNAs that could be regulated by E2. Among these
estrogen-regulated miRNAs, miR-34b was selected for
further investigation because it has been reported to be
a tumor suppressor in colorectal cancer [18], prostate
cancer [25] and gastric cancer [24]. In this study, we
have demonstrated for the first time that miR-34b sig-
nificantly regulates the growth of ER+ breast cancer
cells in vitro. We provide evidence that miR-34b plays a
pivotal role in the human breast cancer-expressing ER+
phenotype (Figure 8). By establishing Tet-On-inducible
miR-34b expression in MCF-7 cells, we have demon-
strated that the induction of miR-34b significantly
decreases cell proliferation rate in vitro and greatly
Figure 7 miRNA (miR)-34b/c suppresses cell gr o w t hi nb r e a s tc a n c e rc e l ll i n e s . Cell proliferation assay of breast cancer cell lines after
overexpression miR-34b/c (n = 6). A 3-(4,5-dimethylthiozol-2-yl)-2,5-diphenyltetrazolium bromide assay was used to monitor viable cell numbers
48 hours after transfection of miR-34b/c precursor cells. CTRL = control. The results represent means ± SD. *P < 0.05.
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Page 12 of 16Figure 8 Schematic illustrating estrogen-dependent regulation of miRNA (miR)-34b expression, its target genes and tumor growth.
The role of estrogen in the miR-34b-regulating pathway is shown. Under 17b-estradiol (E2)-free conditions, p53 and estrogen receptor (ER) bind
to the miR-34b promoter and activate its transcription. However, in the presence of E2 or xenoestrogens, the activated ER disrupts the binding
of the p53-ER complex to the miR-34b promoter region, which subsequently inhibits the tumor-suppressing network and promotes cell
proliferation and tumor progression.
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model in vivo. We have further demonstrated that the
activation of ER by E2 impairs the binding of p53 to the
two p53RE regions of the miR-34b promoter leads to
repression of miR-34b expression.
In this study, we observed that the expression of miR-
34b was downregulated by ER signaling, thus we provide
evidence of the negative correlation between ER and
miR-34b expression levels in patients with ER+ tumors
(Figure 1B). The clinical data derived from our experi-
ments show no significant correlation of miR-34b in
ER- tumors (Figure 1C). We believe that miR-34b is not
likely the only factor involved in tumor progression in
ER- breast cancer patients. Since the malignancy in ER-
breast cancer patients, and even in patients with triple-
negative breast cancer, is quite complicated and since
multiple factors might be involved, the malignancy does
not rely only on miRNAs. Researchers in recent studies
have pointed out that numerous signaling pathways,
including the epidermal growth factor receptor, HER2,
IGFR and BRCA1/2 pathways [3,36,37], could contribute
to the malignancy of ER- breast cancer. On the other
hand, ER+ breast cancer cells are not as malignant, and,
in addition, the patterns of their malignancy are usually
simpler than those of ER- cells, which may be the rea-
son why the miR-34b expression pattern in ER+ cancer
patients is more consistent and more important than
that in ER- cancer patients.
Previous studies indicated that miR-34b/c expression
is regulated by p53, which mediates cell-cycle arrest and
promotes apoptosis [17,38]. DNA damage or aberrant
cell-cycle progression leads to rapid increase of p53,
which in turn may lead to p53-dependent miR34b
expression [16]. Overexpression of miR34b decreases
the expression of a number of cell-cycle regulatory pro-
teins, including cyclin D1, c-MET and CDK4 [15,17,23],
and thus hampers cell-cycle progression [15,16]. In this
study, we confirmed that p53 participates in miR-34b
regulation and leads to cell growth inhibition by target-
ing cyclin D1. In addition, our computational analysis of
miR-34b/c targets using PicTar and miRanda pointed to
the Notch ligand JAG1 as another possible target. In
agreement with these data, we found that miR-34b
inhibited breast cancer cell proliferation by targeting
cyclin D1 and JAG1.
Although many reports have described the regulation
of the miR-34 family as being mediated mostly through
the p53 signaling pathway [15-17,39], miR-34b/c could
also be regulated by DNA methylation of CpG islands
[18,40,41]. Our results show that treatment with 5-aza-
dC (a DNA methyltransferase inhibitor) did increase the
expression of miR-34b/c, but that the methylation status
of miR-34b/c promoter was not affected by E2 treat-
ment. Thus it seems unlikely that E2 regulates miR-34b/
c expression through epigenetic regulation. Given that
E2 significantly repressed the binding of both p53 and
ER to the p53 binding sites in the miR-34b/c promoter,
E2’s binding to ER may change the conformational
structure of ER, which in turn alters p53’sb i n d i n gt o
the miR34-b/c promoter because of ER-p53 protein-pro-
tein interactions.
TAM has been used to treat breast cancer for over 20
years [42]. It has been shown that breast cancer patients
bearing ERa+ and wild-type p53 phenotypes respond
better to TAM therapy [43,44]. In contrast, breast can-
cer patients bearing p53 mutations have a worse prog-
nosis and tend to develop drug resistance earlier [45].
Since the regulation of miR-34b/c is dependent on both
active ERa a n dp 5 3 ,i tp r o v i d em o r eh i n t st h a tE R +
breast cancer patients with wild-type p53 expression
might be more responsive than patients with mutant
p53 to TAM therapy. On the other hand, TAM is a
well-known mixed antagonist/agonist of ER. Depending
on cellular context, TAM may act as an intermediate
agonist or antagonist [42]. In the endometrium, TAM
serves as an agonist to activate gene transcription and
thus contributes to the elevated incidence of endome-
trial tumors in women [46]. We have examined the reg-
ulation of miR-34b in both OVCAR4 and endometrial
cells. We found that E2 exerts similar miR-34b repres-
sion effects in human ovarian cancer cell OVCAR4 cells
and mouse primary cultured endometrial cells, suggest-
ing that a general repression mechanism by miR-34b
may exist in different tissue types.
Current clinical management of breast cancer relies on
various pathological markers to provide suitable therapy.
In our study, miR-34b has been showed to inhibit cell
growth by targeting cyclin D1 and JAG1, both of which
are crucial genes covering various types of breast cancer
[27,47,48]. Moreover, overexpression of miR-34b leads
to inhibition of cell growth in breast cancer cells with
different ER and p53 status. These results indicate that
miR-34b could be a potential therapeutic target in the
treatment of various types of breast cancer.
Conclusions
In summary, E2 may enhance breast cancer growth by
modulating cell-cycle-related genes through the repres-
sion of miR-34b. These findings suggest that miR-34b
can be considered a new marker for the diagnosis of ER
+ breast cancer. Furthermore, miR-34b might be used as
a therapeutic target for treating breast cancer.
Additional material
Additional file 1: Supplementary Table 1 Sequences of primers used
in this study. Additional experimental data and sequences of primers
used in cloning and quantitative RT-PCR.
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Page 14 of 16Additional file 2: Supplementary Figure 1 Cell viability of Mock and
pTRE-miR-34b/Tet-On in the presence or absence of doxycycline
(Dox) (2 μg/ml) were detected by performing a 3-(4,5-
dimethylthiozol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay
(n =3 ) .
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